Paper - WANFANG MED ONLINE

You Position: Home > Paper

胎盘植入的血清学诊断进展

( views:169, downloads:145 )

Author:: No author available

Journal Title:: China Medicine

Issue:: 7

DOI:: 10.3760/cma.j.issn.1673-4777.2015.07.046

Key Word:: 胎盘植入;血管内皮生长因子;可溶性酪氨酸激酶受体-1;胎盘游离mRNA;胎儿游离DNA

Abstract：胎盘植入是由于子宫底蜕膜发育不良或无蜕膜而使胎盘绒毛侵入或穿透子宫肌层所致的一种异常胎盘种植情况,包括胎盘粘连、植入性胎盘以及穿透性胎盘[1].剖宫产史是胎盘植入重要的危险因素,Clark和Silver[2]研究显示胎盘植入的发生率与剖宫产次数成正相关,无剖宫产史孕妇胎盘植入患病率为0.24％,而有3次、4次甚至5次剖宫产史的孕妇胎盘植入患病率明显升高,分别为0.57％、2.13％、2.33％;其他子宫手术史(如子宫肌瘤切除术、刮宫术等)导致的子宫内膜损伤也与胎盘植入发生相关;而高龄孕妇及前置胎盘是胎盘植入的2个独立危险因素.

Reference

[1]吴国.正常妊娠妇女血清AFP,E3检测的临床意义[J].2004,(5).
[2]彭丽平,颜和芳,张平.凶险型前置胎盘对孕产妇危害性的临床分析[J].2012,(21).
[3]周晓.凶险型前置胎盘孕妇肌酸激酶检测的产前诊断价值[J].2014,(3).
[4]孙江川,董晓静,刘建,等.胎盘植入产妇血清肌酸激酶的变化[J].2006,(10).
[5]廖镜芳,周冬梅,钟东彩.晚期妊娠凶险型前置胎盘23例临床分析[J].2010,(5).
[6]廖华,曾蔚越.前置胎盘产前诊断研究进展[J].2009,(10).
[7].Abnormal vascular architecture at the placental-maternal interface in placenta increta[J].2012,207(3).
[8]Kim S,Kamel Reid S,Liu X,etc.Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.[J].2010,21(6).
[9].Does soluble fms-like tyrosine kinase-1 regulate placental invasion? Insight from the invasive placenta[J].2014,210(1).
[10]El Alfy Y,Rasha L E,El Behery MM.Cell-free placental mRNA in maternal plasma to predict placental invasion in patients with placenta accreta.[J].2010,109(1).
[11]Maruo T.Progesterone, thyroid hormone and relaxin in the regulation of the invasive potential of extravillous trophoblasts in early placental development.[J].2010,26(9).
[12]Akihiro Kawashima,Akihiko Sekizawa,Walter Ventura,etc.Increased levels of cell-free human placental lactogen mRNA at 28-32 gestational weeks in plasma of pregnant women with placenta previa and invasive placenta.[J].2014,21(2).
[13]Goh, W.,Yamamoto, S.Y.,Thompson, K.S.,etc.Relaxin, Its Receptor (RXFPI), and Insulin-Like Peptide 4 Expression Through Gestation and in Placenta Accreta[J].2013,20(8).
[14]Clark,E.A.S.,Silver,R.M..Long-term maternal morbidity associated with repeat cesarean delivery[J].2011,205(6 Suppl.).
[15]Alexander,J.M.,Wortman,A.C..Placenta Accreta, Increta, And Percreta[J].2013,40(1).
[16]Lakshmi Tanuja Petla,Rosy Chikkala,K.S. Ratnakar,etc.Biomarkers for the management of pre-eclampsia in pregnant women[J].2013,138(1).
[17]Alberry M,Maddocks D,Jones M,etc.Free fetal DNA in maternal plasma in anembryonic pregnancies: confirmation that the origin is the trophoblast.[J].2007,27(5).
[18]Dugoff L.First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes.[J].2010,115(5).
[19]Niikawa N,Yoshiura K,Nakayama D,etc.Increased level of cell-free placental mRNA in a subgroup of placenta previa that needs hysterectomy.[J].2008,28(9).
[20]Lo YM,Corbetta N,Sargent IL,etc.Presence of fetal DNA in maternal plasma and serum.[J].1997,350(9076).
[21]Jenn-Jhy Tseng,Min-Min Chou.Differential Expression of Growth-, Angiogenesis- and Invasion-Related Factors in The Development of Placenta Accreta[J].2006,45(2).
[22]Rao,K.P.,Yankowitz,J.,Belogolovkin,V.,etc.Abnormal placentation: Evidence-based diagnosis and management of placenta previa, placenta accreta, and vasa previa[J].2012,67(8).
[23]C, Zelop,A, Nadel,F D, Frigoletto,etc.Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein.[J].1992,80(4).
[24]Ella Ophir,Renee Tendler,Marwan Odeh,etc.Creatine kinase as a biochemical marker in diagnosis of placenta increta and percreta[J].1999,180(4).
[25]Alain, Gagnon,R Douglas, Wilson,Fran?ois, Audibert,etc.Obstetrical complications associated with abnormal maternal serum markers analytes.[J].2008,30(10).
[26]N, Vitoratos,D, Hassiakos,C, Iavazzo.Molecular mechanisms of preeclampsia.[J].2012,2012.
[27]Borras,D.,Perales-Puchalt,A.,RuizSacedón,N.,etc.Angiogenic growth factors in maternal and fetal serum in pregnancies complicated with intrauterine growth restriction[J].2014,34(3).
[28]Irina, Manokhina,Tanjot K, Singh,Maria S, Pe?aherrera,etc.Quantification of cell-free DNA in normal and complicated pregnancies: overcoming biological and technical issues.[J].2014,9(7).
[29]Dreux,S.,Salomon,L.J.,Muller,F.,etc.Second-trimester maternal serum markers and placenta accreta[J].2012,32(10).
[30].Fraction of cell-free fetal DNA in the maternal serum as a predictor of abnormal placental invasion-a pilot study[J].2013,33.
[31]Zhao G,Sfakianaki AK,Wehrum MJ,etc.Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast.[J].2011,204(5).
[32]Giese A,Grunewald FS,Prota AE,etc.Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling.[J].2010,1804(3).